485 results about "Antibody titer" patented technology

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic polypeptide. The method comprises the following steps: synthesizing a "CGAGAGSGAGAGS" polypeptide sequence by utilizing an Fmoc method, coupling the polypeptide with keyhole limpet hemocyanin (KLH) through the cysteine on the N terminus of the polypeptide so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain a primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antibody titer in the rabbit blood sample reaches 1/10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate.

The invention provides an ELISA kit for detecting titer of novel coronavirus neutralizing antibody. The kit comprises an elisa plate coated with biotin-streptavidin labeled human ACE2 protein, horseradish peroxidase labeled novel coronavirus RBD protein, a novel coronavirus neutralizing antibody positive control, a coating solution, a washing solution, a diluent, a confining solution, a developingsolution, a stop solution and the like. The kit has the characteristics of low cost, simple operation, high sensitivity, high specificity and high accuracy, and can be used for batch and rapid detection of novel coronavirus neutralizing antibodies.

Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.

A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein <=2x10--9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.

Disclosed herein is a lateral flow immuno-assay system capable of rapidly, cost effectively, and quantitatively detecting and assessing the level of HIT antibodies in body fluids of a patient. Also taught are methods for employing the system to assist in diagnosis of HIT, and for screening or detecting a changing titer of HIT antibodies in the body fluids of a patient to determine susceptibility toward HIT.

The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to decrease proteinuria levels and antinuclear antibody titers in SLE mammals in order to alleviate kidney inflammation and disease, as well as the self-damage caused by antinuclear antibodies. The purpose for prevention and treatment of autoimmune diseases and kidney diseases by the natural, side-effect free substance can then be accomplished.

The invention aims at providing a new castle disease and H9 subtype bird flu bivalent vaccine. The new castle disease and H9 subtype bird flu bivalent vaccine contains antigens and adjuvant. The antigens are inactivated H9 subtype bird flu viruses and new castle disease viruses. The H9 subtype bird flu viruses are QDY strains, and the preservation number of the H9 subtype bird flu viruses is CCTCC v201517. The QDY strains of the H9 subtype bird flu viruses and a Lasota strain of the new castle disease viruses are inoculated to chick embryos respectively, and then virus liquid is collected; the virus liquid and the oil adjuvant are mixed and emulsified into the vaccine after the virus liquid is inactivated through a formaldehyde solution. The new castle disease and bird flu bivalent inactivated vaccine is good in immunogenicity, antibody production is fast after immunity, the produced antibody titer is high, the produced antibody holding time is long, the retention period is long, the immunizing dose is small, the selected adjuvant is easy to inject, and two kinds of diseases can be prevented through one-time injection. The vaccine has the advantages of being efficient and good in safety.

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.

The invention discloses a duck egg yolk antibody for preventing and treating virus hepatitis of ducklings, and a preparation method thereof. The duck egg yolk antibody is extracted from the primiparous eggs of a high-immunity homebred breed duck starting laying for one month. The preparation method comprises the following steps of: (a) highly immunizing the breed duck before laying; (b) collecting high-immunity primiparous breed duck eggs; (c) cleaning and sterilizing; (d) separating egg yolks; (e) diluting; (f) stirring and filtering; and (g) packaging and preserving. After the egg yolks are continuously diluted for 2 times by using normal saline, the DHV (Duck Hepatitis Virus) precipitating antibody is detected by a conventional method, the antibody titer is more than 1:64, and the HI titer of H5 is more than 1:512. 0.5mL of the duck egg yolk antibody is subcutaneously injected to a 3-day-old duckling for preventing virus hepatitis; and 1mL of egg yolk antibody to which antibiotics are added is subcutaneously injected to a duck for treating virus hepatitis, and the egg yolk antibody is re-injected to a seriously diseased duck every other day.

The invention relates to human rotavirus Delta VP8* subunit recombinant protein and application thereof. The human rotavirus Delta VP8* subunit recombinant protein comprises a T cell epitope P2 in tetanus toxin and a rotavirus Delta VP8* subunit. By the recombinant protein disclosed by the invention, the immune efficacy of a Delta VP8* subunit vaccine can be greatly improved; faster and stronger neutralization antibody titer can be induced; moreover, anti-p[4] genotype specific rotavirus cross neutralization antibody of high titer can be induced; simultaneously, the potential risk of inducing intussusception by taking attenuated rotavirus vaccine orally can be overcome; therefore, the recombinant protein is applicable to preparing a rotavirus vaccine.

A method and apparatus for measuring antibody titers in a thin film sample in an automated system which does not require multiple dilutions. The system provides a simple method for creating an in-situ dilution within a sample analysis chamber without the use of any precision fluid-handling components, and further, to use the same principles to provide a wide range of sample dilutions within the chamber so as to obviate the need for additional dilution steps when dealing with samples possibly containing wide ranges of analyte concentrations.

The invention relates to a preparation method of an inactivated newcastle disease vaccine. The preparation method comprises the steps of virus liquid inactivation, preparation of a compound traditional Chinese medicine extract, preparation of an aqueous phase, preparation of an oil phase and emulsification. According to the preparation method, the compound traditional Chinese medicine extract serving as an immunopotentiator is added to the inactivated newcastle disease vaccine so as to well cause cellular immunologic response and enhance the immunologic function of an organism, so that an antibody is generated in advance, and the antibody titer is obviously improved.

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg/mL of poly IC, 10ng-10mg/mL of muramyl dipeptide, 10ng-5mg/mL of levamisole, 10ng-5mg/mL of resiquimod and 10ng-5mg/mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

The invention relates to the field of immunology, in particular a preparation method of duck hepatitis antibody. The preparation method comprises the following steps: (1) feeding healthy laying hens by poplar bark lipoid at a dosage of 0.08 to 0.1g per hen each day; carrying out duck hepatitis inactivated vaccine intensive immunity for healthy laying hens fed by poplar bark lipoid after 20 to 30 days; collecting hen blood serum to measure anti-DHV neutralizing antibody titer; and collecting eggs laid by qualified flocks; and (2) separating egg white under aseptic conditions, mashing yolk and evenly mixing the yolk liquid with aseptic physiological saline to prepare yolk antibody. Compared with the antibody from mammals, antibody prepared through the preparation method has the advantages of convenient material sources, simple separation and purification method, high yield, high specificity and better stability.

The invention discloses a green tea composite chicken feed additive capable of enhancing the immunity of chickens. The additive is prepared from summer and autumn tea, dandelion, folium cortex eucommiae, radix isatidis, gouttuynia cordata, liquorice and the like, and has multiple effects of resisting bacteria and viruses, enhancing the immunity of animals and the like. A feeding test shows that the additive can improve all immune indexes, such as the serum newcastle disease antibody titer, the serum immune globulins and immune organ indexes, of laying hens and meat chickens; meanwhile, compared with an antibiotic added experimental group, the breeding test has the advantage that the death rate of animals in a treatment group does not have an obvious difference. The green tea composite chicken feed can be used as an additive for healthy breeding of the laying hens and the meat chickens; the raw materials are readily available and low in cost; the green tea composite chicken feed additive has a wide market prospect and high social and economical benefits.

The invention discloses a foot and mouth disease virus-like particle vaccine and a preparation method thereof. By expressing P12A (three amino acid site mutation, VP1K210E, VP1E83K and VP1C134S) and serum-free suspension culture, a virus-like particle (VLP) standard similar to natural 75S FMDV is built, and VLP yield is increased. The invention further provides serum-free suspension cultured and high pH tamed insect cells, the insect cells can stably and efficiently produce FMDV VLP, the size and structure of the VLP produced by the insect cells is similar to those of the VLP produced by standard BHK-21, and the yield of the VLP produced by the insect cells is 11 times of that of the VLP produced by female parent cells Sf21. The vaccine prepared by the VLP produced by the insect cells can immunize animals to generate IgG antibody response. The IgG antibody titer, foot and mouth disease virus neutralizing antibody titer and antibody titer of immunization of the VLP vaccine produced by the insect cells are not evidently different from those of immunization of the VLP vaccine prepared by the BHK-21, so that the high-pH-adaptive insect cells are applicable to FMDV VLP vaccine production.

The disclosure describes compositions containing conjugates using novel linkers, bivalent polysaccharide conjugates, and methods of bivalent polysaccharide conjugation in the development of multivalent conjugate vaccines. Conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of the linkers and their use in bifunctional linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are conjugated sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent conjugate vaccine with high antibody titers and a reduced carrier effect and results in reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.

The invention relates to the technical field of biomedicine, and particularly provides a fusion protein of an SVV and an FMDV, an encoding gene of the fusion protein, an expression vector, a cell line, engineering bacteria, a vaccine and application. The fusion protein is obtained by replacing an epitope capable of inducing the body to produce a neutralizing antibody with a decoy epitope and comprises SVV VP1 protein fragments, FMDV VP1 protein fragments and complement C3d protein fragments. The fusion protein combines antigens for inducing the body to produce the neutralizing antibody, of twopathogens of SVV and FMDV, and the safety of the antigens is improved while the antigenic epitopes of the SVV and the FMDV are reserved. The complement C3d molecules can excite nonspecific body fluidand cellular immune reactions in the body, and play an important role in increasing the antibody titer of the vaccine, and activating the cellular immune response of the body. The vaccine prepared bymeans of the fusion protein is safe and effective, and hydroa and foot-and-mouth diseases can be effectively prevented.

The invention discloses a compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant, the partical size of which is between 1nm and 100nm, and is composed by echinacea purpurea herb, astragalus polysaccharides, surface active agent, cosurfactant, oil and distilled water. The product presents clear light yellow liquid, has the partical size smaller than 100nm, has lower viscosity and better stability, does not need special emulation when seedling, and has low requirements on equipment and easy controlled product quality. By taking albumin egg OVA as model antigen, tests show that the compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant of the invention has better immunoreaction than using aluminium adjuvant in a certain dosage, has higher antibody titer, reduces the dosage of oil or antigen in the adjuvant, stimulates the reaction of Th1 and Th2, increases the immunization of the liquid and the cell of the an organism, and plays a good role of immune protection of the organism.